---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012844"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:56:38.785408+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech receives Nasdaq deficiency notice for bid price below $1.00; compliance deadline Nov 1, 2023

## Summary
- Received Nasdaq deficiency letter on May 5, 2023 for failing minimum $1.00 bid price for 30 consecutive days.
- Has 180 days until November 1, 2023 to regain compliance by closing at $1.00+ for at least 10 business days.
- If non-compliant by Nov 1, may qualify for second 180-day period if meets other listing standards.
- Company may consider a reverse stock split to cure deficiency, but no assurance of success.
- No immediate delisting; can appeal any delisting determination to a Nasdaq Listing Qualifications Panel.

## SEC filing metadata
- accession: 0001437749-23-012844
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923012844/0001437749-23-012844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923012844/mbrx20230505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012844
- JSON: https://secwatch.observer/filing/0001437749-23-012844.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012844.txt

## Key facts
- Listing & Compliance Notices
  Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)
  source text: May 5, 2023, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In ac
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923012844/0001437749-23-012844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.